Company and Stock Identity

How Brainomix Connects to the Public Market

Company structure
Private company
Market access
No current public listing was verified.
Research focus
Treat the stroke product and the lung product as two separate purchases, because different people judge them on different proof. Boehringer Ingelheim selected e-Lung as a co-primary endpoint in a Phase 3 trial, which is a different claim than a hospital deployment, and neither one carries over to the other product.

Brainomix Limited is a University of Oxford spinout, registered in England and Wales as company 07426406 with offices in Oxford. On February 24, 2026 the company said it extended its Series C financing to 25.4 million dollars, or 18.8 million pounds, with existing investors Parkwalk and Hostplus leading and US investor Modi Ventures joining. No ownership change was found as of October 10, 2026.

Open the public company market data feed for the full directory, ownership relationships, stock identifiers, and dated snapshots.

First-Hand Company News

Latest Developments

... Brainomix ... Company source

Brainomix says Phase III lung trial data shows CT measurement can track fibrosis

Brainomix said on 1 October 2026 that new data from the Phase III INBUILD trial highlights the potential of quantitative CT to predict disease progression and assess treatment response in progressive pulmonary fibrosis. The trial is a Boehringer Ingelheim study, and Brainomix has described an ongoing partnership with that company in pulmonary fibrosis since May 2026. The announcement states the potential and the two intended uses but does not publish any effect sizes, accuracy figures or outcome numbers, and makes no regulatory claim for the use it describes.

Why it matters: A drug trial using an imaging measurement as a way to judge whether treatment is working is a different and more valuable business than selling software to a hospital, because a sponsor will pay for a measurement it can defend to a regulator. That is why this is worth watching even without figures. The absence of figures is also the point: predicting progression from a CT scan is a research finding here, not a cleared use, and the company's FDA-cleared e-Lung product measures features on a scan rather than forecasting a disease course. Wait for the published analysis before treating this as established.

... Brainomix ... Company source

Brainomix CT analysis measured lung change in an Endeavor BioMedicines trial

Brainomix said on September 8, 2026 that it and Endeavor BioMedicines presented results from the ENV-IPF-101 Phase 2a trial of taladegib at the European Respiratory Society Congress 2026. Brainomix says the analysis used Brainomix 360 e-Lung for AI-powered quantitative CT analysis, and that the trial showed significant treatment effects across several measures of lung structure and fibrosis. The announcement states no regulatory status for the results.

Why it matters: Being picked as the measuring tool inside a drug trial is a different kind of credit from a sales reference, because a sponsor filing can end up resting on that measurement. The results described here belong to the trial, not to the tool, so they show the measurement moved along with the drug rather than showing e-Lung is accurate on its own in routine care. For a hospital buyer the useful question is whether trial-grade readings need trial-grade scan settings that a busy clinic will not match.

... Brainomix ... Company source

WVU Health System puts Brainomix stroke AI in all 25 of its hospitals

Brainomix said on 11 March 2026 that it deployed Brainomix 360 Stroke across the West Virginia University Health System, covering all 25 hospitals in the network, and describes it as the first time the entire WVU network has run on a single unified AI solution. The company says the aim is faster acute stroke decisions and more consistent care across rural and urban facilities. It also cites a Lancet Digital Health paper from 2025 reporting a 100 percent increase in thrombectomy rates across 452,000 patients at 107 hospitals over five years.

Why it matters: Standardising on one platform across a network matters more in stroke than in most specialties, because the decision to transfer a patient depends on everyone reading the scan the same way, and a rural hospital with no neurointerventional team has to trust what the city hospital will do with its images. The published Lancet Digital Health figure is the strongest evidence on this profile and it is independent of this deployment, covering a different set of 107 hospitals, so treat it as context rather than a prediction for West Virginia. A doubling of thrombectomy rates also reflects a whole care pathway changing, not software alone.

... Brainomix ... Company source

Brainomix extends its Series C to 25.4 million dollars for a push into the United States

Brainomix said on 24 February 2026 that it extended its Series C financing to 25.4 million dollars, or 18.8 million pounds, led by existing investors Parkwalk and Hostplus with the new United States investor Modi Ventures taking part. The company says the money will improve customer support and speed up product work across its Brainomix 360 Stroke and e-Lung platforms. It cites a Lancet Digital Health paper from 2025 reporting a 100 percent increase in thrombectomy rates across 452,000 patients at 107 hospitals over five years.

Why it matters: Bringing in a United States investor alongside the existing British and Australian backers is the signal in this round, because an expansion into American hospitals needs local relationships more than it needs cash. The sum is modest next to the hundreds of millions raised by American imaging AI companies, which means Brainomix has to win on evidence rather than on sales coverage, and the Lancet paper is the evidence it leans on. A hospital signing during a build-out phase should pin down support hours in its own time zone rather than assume them.

... Brainomix ... Company source

Brainomix launches next generation stroke AI that measures brain water on a plain CT

Brainomix announced on February 2, 2026 the launch of Brainomix 360 Stroke Next Generation at the International Stroke Conference. The company says the release carries an industry-first net water uptake biomarker, which it describes as giving clinicians a deeper view of how severe a stroke injury is directly from a non-contrast CT scan rather than from advanced imaging. Brainomix says the platform won a Red Dot Design Award for usability and innovation, and that more than 60 peer-reviewed studies have examined Brainomix 360.

Why it matters: Reading injury severity from a plain CT matters because a plain CT is the scan a small hospital actually has at 3am, while advanced imaging often means moving the patient somewhere else first. Brainomix presents net water uptake as something that helps a clinician judge severity, which is a long way from proof that it changes a treatment decision, and the launch page does not say which United States regulatory status covers this release or which finding it covers. A design award means the screen is easier to read, and nothing more than that.

See company developments across the healthcare AI market.

Careers and Qualifications

What to Know Before Applying

Work areas: Hiring runs through the company's own Workable job board, which describes Brainomix as an Oxford spinout building AI imaging software and lists its current openings there.

Qualification signal: Stroke pathway or respiratory trial experience is the real signal, because these products sit inside time-pressured treatment decisions and clinical trial endpoints rather than back-office workflow.

Check current roles at Brainomix. A careers page is the source of record for openings. This profile does not claim a role is open unless the company lists it now.

Related Healthcare AI Roles

Training to Compare

Buyer Snapshot

Best-fit buyer
Radiology leadership, pathology leadership, clinical informatics, imaging IT, patient safety, and procurement
Primary use case
Triage studies, flag findings, support image interpretation, and coordinate time-sensitive care
Typical deployment
Usually integrated with PACS, RIS, worklists, or digital pathology systems and monitored inside the clinical workflow

Evidence questions

  • Was the tool tested prospectively and independently on comparable equipment and patients?
  • What are sensitivity, specificity, false positive workload, and time-to-action effects?
  • How does performance vary by site, scanner, demographic subgroup, and disease prevalence?

Regulatory and workflow questions

  • Which FDA authorization covers the exact product version, modality, and intended use?
  • Who retains final clinical responsibility and how is disagreement with the AI handled?
  • What post-deployment monitoring and material update notification does the vendor provide?

Data and contract questions

  • Where are images and derived data processed and retained?
  • Which PACS, RIS, pathology, and EHR integrations are supported in production?
  • Can data be used for model improvement, and what controls govern secondary use?

Evidence and Regulation

FDA Clearances on Record

Brainomix appears on 6 cleared products in the federal 510(k) record, across 2 device types.

A clearance means the FDA agreed the product is close enough to something already on the market to be sold for that use. It is not a finding that the product helps patients, and it is not a ranking against anything else on this page. A company is linked to an FDA clearance only when the 510(k) applicant name on the government record is confirmed by hand to be that same company, including former corporate names. Name similarity alone is never enough, and rejected matches are listed below with the reason.

What the Published Research Says About This Work

Independent studies on the work itself help separate category evidence from one company's claims.

First-Hand Sources